Company / EPS (Diluted)
BioAge Labs, Inc. EPS (Diluted) History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$6.63
FY2025
5-year range
-$38.17 / -$6.63
FY2023-FY2025
Trend
+0.0%
vs FY2024
Sector context
#192 of 204
Health Care
What the data says
Among 204 Health Care companies, BioAge Labs, Inc. is in the bottom 6% for eps (diluted). Improved from $-38.17 to $-6.63 over the past 2 years.
Based on SEC 10-K filings.
-6.63 in FY2025.
Improved from $-38.17 to $-6.63 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 6% in Health CareTop 94% of 204This company -$6.63 Sector average -$0.89
▼
-648.1% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 0.0% year-over-year.
- Ranks #192 out of 204 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 3.75 (safe zone, above 2.9 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$6.63 | +0.0% |
| FY2024 | -$6.63 | +82.6% |
| FY2023 | -$38.17 | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026